Viz.ai, A company that is involved in AI-supported image and care coordination works together with pharmaceutical giant Novartis to develop its own AI-drive workflows in the Nevel-Oncology package.
VIZ.AI offers a care coordination platform with more than 50 by the FDA that helps to analyze medical imaging data to provide insight into diagnoses, to facilitate workflows and support decisions about treatment.
The companies will focus on improving the “identification and stratification of patients with the diagnosis of prostate and breast cancer based on crucial risk factors, which accelerates access to precision treatments based on guidelines.”
The cooperation also focuses on tackling delays in the diagnosis and treatment by using AI to ensure that patients are identified and previously treated with timely, coordinated care.
Viz.ai is van plan om twee nieuwe AI-aangedreven aanbiedingen te ontwikkelen: namelijk prostaatkanker, ontworpen om in aanmerking komende patiënten te identificeren voor richtlijngebaseerde behandeling met doorverwijzingen naar een toepasselijke specialist, en namelijk borstkanker, een aanbod dat borst-oncologen ondersteunt door patiëntrecensies te automatiseren, risico-relevante gegevens verzamelen, therapeutische richtlijnen en promotiecoördinatie tussen multidisciplineren between multidisciplinary teams.
“We are pleased to work with Novartis, an innovative medicine company and a leader in oncology, to speed up access to timely, guidelines-based care for patients confronted with prostate and breast cancer,” Dr. Chris Mansi, CEO and co-founder of Viz.ai, in a statement.
“This collaboration is part of our broader strategic expansion into oncology, so that the mission of VIZ.AI would fundamentally transform healthcare through intelligent care coordination.”
The larger trend
In May, Viz.ai worked with Regeneron, a biotechnology company, and Sanofi, a biopharmaceutical company, to use and study an AI-compatible workflow tool for COPD.
Via the partnership, Sanofi and Regeneron will support VIZ.AI into its VIZ COPD module, which uses AI and electronic health data to identify and manage COPD patients with a high risk.
In 2023, viz.ai a signed Multi-year agreement with Bristol Myers Squibb to give an AI-enabled Algorithm and software for provider workflow, called VIZ HCM.
VIZ HCM is used to help identify and assess patients on hypertrophic cardiomyopathy by assessing routine electrocardiograms and identifying probable cases for clinical assessment. It was integrated into the range of Viz.ai’s Cardio Suite.
In 2023, Dawn Health has entered into a strategic partnership with Novartis to develop a chronic platform for fitness management.
Under the cooperation, Dawn and Novartis have built external monitoring and management aids for chronic conditions where they see an unfulfilled need and ensure disease progression, such as multiple sclerosis, hypertension, cardiovascular disease and breast cancer.
The platform includes mobile apps for patients, symptom monitoring, digital biomarkers, clinical decision support services and virtual clinical offers made for specific diseases and disorders.
In 2022, Anumana, a joint venture between Nference, an EPD data company and the Mayo Clinic, entered a strategic partnership with Novartis to develop artificial intelligence tools for detecting cardiovascular disorders.
The collaboration was aimed at using AI algorithms that analyze ECGs to find left ventricular dysfunction, which can lead to heart failure and atherosclerotic cardiovascular diseases.
#Viz.ai #Novartis #Partner #AIdriven #care #patients #cancer